Back to results
US 2006/0233782 A1Published application
Proteoglycan degrading mutants for the treatment of CNS
AssigneeAcorda Therapeutics, Inc.
InventorsElliott Gruskin, Rohini D'Souza, Gargi Roy, Anthony Caggiano
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.
Claims42
An composition comprising:
- an isolated nucleic acid comprising a sequence that encodes for mutant proteoglycan degrading polypeptide.
An composition comprising:
- an isolated nucleic acid consisting of a sequence a sequence that encodes for a biologically active mutant proteoglycan degrading polypeptide.
A composition comprising:
- a polypeptide comprising the amino acid sequence of a biologically active mutant proteoglycan degrading polypeptide.
A method of treating a tissue, the method comprising:
- administering a mutant proteoglycan degrading polypeptide composition to the tissue, said tissue including proteoglycan molecules, said composition degrading at least a portion of the proteoglycan in the tissue.
A purified chondroitinase mutant polypeptide that degrades a proteoglycan.
Dependencies are inferred from the claim text.